Clinical characteristics of dUCBT recipients with varying numbers of NK cells at D+28 posttransplantation
| Variable . | NK low (n = 40) . | NK medium (n = 37) . | NK high (n = 34) . | P . |
|---|---|---|---|---|
| Age at transplant, y (%) | .99 | |||
| 0-19 | 5 (13) | 5 (14) | 5 (15) | |
| 20-49 | 14 (35) | 11 (30) | 9 (26) | |
| 50-59 | 8 (20) | 7 (19) | 8 (24) | |
| 60-73 | 13 (33) | 14 (38) | 12 (35) | |
| Sex (%) | .20 | |||
| Male | 25 (63) | 28 (76) | 19 (56) | |
| Female | 15 (38) | 9 (24) | 15 (44) | |
| Conditioning intensity (%) | .70 | |||
| Myeloablative | 15 (38) | 11 (30) | 13 (38) | |
| Nonmyeloablative | 25 (63) | 26 (70) | 21 (62) | |
| Disease type (%) | .57 | |||
| Acute leukemia | 23 (58) | 23 (62) | 19 (56) | |
| Chronic leukemia | 8 (20) | 5 (14) | 11 (32) | |
| Lymphoma | 6 (15) | 6 (16) | 3 (9) | |
| Other malignancy | 3 (8) | 3 (8) | 1 (3) | |
| Transplant number (%) | .39 | |||
| 1 | 35 (88) | 31 (84) | 32 (94) | |
| ≥2 | 5 (13) | 6 (16) | 2 (6) | |
| HLA mismatch (of engrafting unit) (%) | .19 | |||
| 0-2 mismatch | 20 (50) | 25 (68) | 23 (68) | |
| ≥3 mismatch | 20 (50) | 12 (32) | 11 (32) | |
| Days from diagnosis to UCBT (%) | .31 | |||
| 59-180 | 18 (45) | 14 (38) | 19 (56) | |
| >180 | 22 (55) | 23 (62) | 15 (44) | |
| Recipient CMV serostatus (%) | .40 | |||
| Positive | 22 (55) | 15 (41) | 18 (53) | |
| Negative | 38 (45) | 22 (59) | 16 (47) | |
| CMV reactivation | .83 | |||
| (if positive serostatus) (%) | 11 (50) | 10 (67) | 10 (56) | |
| Cell dose × 108/kg | ||||
| Mean (SD) | 0.52 (0.34) | 0.44 (0.20) | 0.60 (0.61) | .61 |
| Cell dose of winning unit | ||||
| Mean (SD) | 0.27 (0.20) | 0.21 (0.11) | 0.34 (0.38) | .09 |
| Number of unique infections | ||||
| Mean (SD) | 1.73 (1.36) | 1.49 (1.35) | 1.71 (1.40) | .70 |
| Days to neutrophil recovery (95%) | ||||
| Median (range) | 22 (13-26) | 18 (9-21) | 17 (13-20) | .09 |
| Variable . | NK low (n = 40) . | NK medium (n = 37) . | NK high (n = 34) . | P . |
|---|---|---|---|---|
| Age at transplant, y (%) | .99 | |||
| 0-19 | 5 (13) | 5 (14) | 5 (15) | |
| 20-49 | 14 (35) | 11 (30) | 9 (26) | |
| 50-59 | 8 (20) | 7 (19) | 8 (24) | |
| 60-73 | 13 (33) | 14 (38) | 12 (35) | |
| Sex (%) | .20 | |||
| Male | 25 (63) | 28 (76) | 19 (56) | |
| Female | 15 (38) | 9 (24) | 15 (44) | |
| Conditioning intensity (%) | .70 | |||
| Myeloablative | 15 (38) | 11 (30) | 13 (38) | |
| Nonmyeloablative | 25 (63) | 26 (70) | 21 (62) | |
| Disease type (%) | .57 | |||
| Acute leukemia | 23 (58) | 23 (62) | 19 (56) | |
| Chronic leukemia | 8 (20) | 5 (14) | 11 (32) | |
| Lymphoma | 6 (15) | 6 (16) | 3 (9) | |
| Other malignancy | 3 (8) | 3 (8) | 1 (3) | |
| Transplant number (%) | .39 | |||
| 1 | 35 (88) | 31 (84) | 32 (94) | |
| ≥2 | 5 (13) | 6 (16) | 2 (6) | |
| HLA mismatch (of engrafting unit) (%) | .19 | |||
| 0-2 mismatch | 20 (50) | 25 (68) | 23 (68) | |
| ≥3 mismatch | 20 (50) | 12 (32) | 11 (32) | |
| Days from diagnosis to UCBT (%) | .31 | |||
| 59-180 | 18 (45) | 14 (38) | 19 (56) | |
| >180 | 22 (55) | 23 (62) | 15 (44) | |
| Recipient CMV serostatus (%) | .40 | |||
| Positive | 22 (55) | 15 (41) | 18 (53) | |
| Negative | 38 (45) | 22 (59) | 16 (47) | |
| CMV reactivation | .83 | |||
| (if positive serostatus) (%) | 11 (50) | 10 (67) | 10 (56) | |
| Cell dose × 108/kg | ||||
| Mean (SD) | 0.52 (0.34) | 0.44 (0.20) | 0.60 (0.61) | .61 |
| Cell dose of winning unit | ||||
| Mean (SD) | 0.27 (0.20) | 0.21 (0.11) | 0.34 (0.38) | .09 |
| Number of unique infections | ||||
| Mean (SD) | 1.73 (1.36) | 1.49 (1.35) | 1.71 (1.40) | .70 |
| Days to neutrophil recovery (95%) | ||||
| Median (range) | 22 (13-26) | 18 (9-21) | 17 (13-20) | .09 |
Patients were divided into tertiles based on the absolute NK number at D+28: low (<50 NK cells/mm3), medium (50-120 NK cells/mm3), and high (>120 NK cells/mm3). Recipient and transplant-specific demographics are shown.
CMV, cytomegalovirus; SD, standard deviation.